Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

(l-r): Professor Ben Davis, Professor Frances Platt, Lord Chris Patten, Professor James Naismith and Dr Paul McCubbin celebrate this strategic partnership © Stuart March
(l-r): Professor Ben Davis, Professor Frances Platt, Lord Chris Patten, Professor James Naismith and Dr Paul McCubbin celebrate this strategic partnership.

Formed around the lab of Professor Ben Davis, Director of Next Generation Chemistry at The Franklin, the partnership will see bilateral movement of researchers between the Franklin and Oxford, widening access to the cutting edge facilities at Harwell.

Professor Frances Platt, Head of Department at the University of Oxford Department of Pharmacology said, “I am delighted that Professor Davis will be joining our department – his research is an excellent fit with existing work taking place in Pharmacology. This partnership with The Franklin offers a wealth of opportunity for our research and academic staff to form exciting new collaborations with world-leading scientists and facilities.”

One of the key aims for the Davis group is to perform ‘in-cell chemistry’ – editing proteins and other biomolecules within the cell for therapeutic or diagnostic purposes. This work is revolutionary in its approach, and is highly complementary to other Franklin themes, including mass spectrometry imaging, structural biology, and correlated imaging.

Read the full story on the Department of Pharmacology website. 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience